S&P 500   4,431.85 (+2.43%)
DOW   34,725.47 (+1.65%)
QQQ   351.80 (+3.14%)
AAPL   170.33 (+6.98%)
MSFT   308.26 (+2.81%)
FB   301.71 (+2.40%)
GOOGL   2,667.02 (+3.37%)
AMZN   2,879.56 (+3.11%)
TSLA   846.35 (+2.08%)
NVDA   228.40 (+4.08%)
BABA   115.23 (+3.08%)
NIO   20.90 (-0.99%)
AMD   105.24 (+2.57%)
CGC   7.27 (+6.13%)
MU   79.27 (+0.70%)
GE   92.10 (+2.45%)
T   25.21 (+4.52%)
F   19.54 (-0.05%)
DIS   138.63 (+2.37%)
AMC   15.06 (+3.72%)
PFE   54.33 (+1.80%)
ACB   3.91 (+3.17%)
BA   190.57 (+0.43%)
S&P 500   4,431.85 (+2.43%)
DOW   34,725.47 (+1.65%)
QQQ   351.80 (+3.14%)
AAPL   170.33 (+6.98%)
MSFT   308.26 (+2.81%)
FB   301.71 (+2.40%)
GOOGL   2,667.02 (+3.37%)
AMZN   2,879.56 (+3.11%)
TSLA   846.35 (+2.08%)
NVDA   228.40 (+4.08%)
BABA   115.23 (+3.08%)
NIO   20.90 (-0.99%)
AMD   105.24 (+2.57%)
CGC   7.27 (+6.13%)
MU   79.27 (+0.70%)
GE   92.10 (+2.45%)
T   25.21 (+4.52%)
F   19.54 (-0.05%)
DIS   138.63 (+2.37%)
AMC   15.06 (+3.72%)
PFE   54.33 (+1.80%)
ACB   3.91 (+3.17%)
BA   190.57 (+0.43%)
S&P 500   4,431.85 (+2.43%)
DOW   34,725.47 (+1.65%)
QQQ   351.80 (+3.14%)
AAPL   170.33 (+6.98%)
MSFT   308.26 (+2.81%)
FB   301.71 (+2.40%)
GOOGL   2,667.02 (+3.37%)
AMZN   2,879.56 (+3.11%)
TSLA   846.35 (+2.08%)
NVDA   228.40 (+4.08%)
BABA   115.23 (+3.08%)
NIO   20.90 (-0.99%)
AMD   105.24 (+2.57%)
CGC   7.27 (+6.13%)
MU   79.27 (+0.70%)
GE   92.10 (+2.45%)
T   25.21 (+4.52%)
F   19.54 (-0.05%)
DIS   138.63 (+2.37%)
AMC   15.06 (+3.72%)
PFE   54.33 (+1.80%)
ACB   3.91 (+3.17%)
BA   190.57 (+0.43%)
S&P 500   4,431.85 (+2.43%)
DOW   34,725.47 (+1.65%)
QQQ   351.80 (+3.14%)
AAPL   170.33 (+6.98%)
MSFT   308.26 (+2.81%)
FB   301.71 (+2.40%)
GOOGL   2,667.02 (+3.37%)
AMZN   2,879.56 (+3.11%)
TSLA   846.35 (+2.08%)
NVDA   228.40 (+4.08%)
BABA   115.23 (+3.08%)
NIO   20.90 (-0.99%)
AMD   105.24 (+2.57%)
CGC   7.27 (+6.13%)
MU   79.27 (+0.70%)
GE   92.10 (+2.45%)
T   25.21 (+4.52%)
F   19.54 (-0.05%)
DIS   138.63 (+2.37%)
AMC   15.06 (+3.72%)
PFE   54.33 (+1.80%)
ACB   3.91 (+3.17%)
BA   190.57 (+0.43%)
NYSE:ASXC

Asensus Surgical Stock Forecast, Price & News

$0.86
+0.04 (+4.91%)
(As of 01/28/2022 04:00 PM ET)
Add
Compare
Today's Range
$0.80
$0.87
50-Day Range
$0.81
$1.50
52-Week Range
$0.73
$6.95
Volume
1.58 million shs
Average Volume
3.00 million shs
Market Capitalization
$200.40 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.44
30 days | 90 days | 365 days | Advanced Chart
Receive ASXC News and Ratings via Email

Sign-up to receive the latest news and ratings for Asensus Surgical and its competitors with MarketBeat's FREE daily newsletter.


About Asensus Surgical

Asensus Surgical, Inc. is a medical device company, which digitizes the interface between the surgeon and the patient to improve minimally invasive surgery through digital laparoscopy. It enables the use of advanced capabilities like augmented intelligence, connectivity and robotics in laparoscopy, and addresses the current clinical, cognitive, economic shortcomings in surgery. The Senhance Surgical System features as the first machine vision system for use in robotic surgery, which is powered by the new Intelligent Surgical Unit (ISU) that enables augmented intelligence in surgery and brings the benefits of digital laparoscopy to patients around the world while staying true to the principles of value-based healthcare. The company was founded by William N. Starling on August 19, 1988 and is headquartered in Morrisville, NC.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Employees
133
Year Founded
N/A

Sales & Book Value

Annual Sales
$3.17 million
Book Value
$0.53 per share

Profitability

Net Income
$-59.31 million
Net Margins
-879.52%
Pretax Margin
-881.51%

Debt

Price-To-Earnings

Miscellaneous

Free Float
232,538,000
Market Cap
$200.40 million
Optionable
Optionable

Company Calendar

Last Earnings
11/03/2021
Today
1/28/2022
Next Earnings (Estimated)
3/09/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

1.26 out of 5 stars

Medical Sector

1193rd out of 1,417 stocks

Surgical & Medical Instruments Industry

116th out of 130 stocks

Analyst Opinion: 3.3Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












Asensus Surgical (NYSE:ASXC) Frequently Asked Questions

Is Asensus Surgical a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Asensus Surgical in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Asensus Surgical stock.
View analyst ratings for Asensus Surgical
or view top-rated stocks.

When is Asensus Surgical's next earnings date?

Asensus Surgical is scheduled to release its next quarterly earnings announcement on Wednesday, March 9th 2022.
View our earnings forecast for Asensus Surgical
.

How were Asensus Surgical's earnings last quarter?

Asensus Surgical, Inc. (NYSE:ASXC) released its quarterly earnings results on Wednesday, November, 3rd. The company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.06) by $0.01. The company earned $2.57 million during the quarter, compared to analyst estimates of $1.02 million. Asensus Surgical had a negative net margin of 879.52% and a negative trailing twelve-month return on equity of 30.34%.
View Asensus Surgical's earnings history
.

What price target have analysts set for ASXC?

2 brokerages have issued 12-month target prices for Asensus Surgical's stock. Their forecasts range from $4.00 to $4.00. On average, they anticipate Asensus Surgical's share price to reach $4.00 in the next year. This suggests a possible upside of 367.8% from the stock's current price.
View analysts' price targets for Asensus Surgical
or view top-rated stocks among Wall Street analysts.

Who are Asensus Surgical's key executives?

Asensus Surgical's management team includes the following people:
  • Anthony Fernando, President Chief Executive Officer & Director (LinkedIn Profile)
  • Shameze Rampertab, Chief Financial Officer & Executive Vice President
  • Cameron Pedersen, Vice President-Global Research & Development
  • Eric Smith, Chief Commercial Officer
  • Mark Klausner, Investor Relations Contact

What is Asensus Surgical's stock symbol?

Asensus Surgical trades on the New York Stock Exchange (NYSE) under the ticker symbol "ASXC."

Who are Asensus Surgical's major shareholders?

Asensus Surgical's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Cutler Group LP (0.00%).
View institutional ownership trends for Asensus Surgical
.

Which major investors are selling Asensus Surgical stock?

ASXC stock was sold by a variety of institutional investors in the last quarter, including Cutler Group LP.
View insider buying and selling activity for Asensus Surgical
or view top insider-selling stocks.

How do I buy shares of Asensus Surgical?

Shares of ASXC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Asensus Surgical's stock price today?

One share of ASXC stock can currently be purchased for approximately $0.86.

How much money does Asensus Surgical make?

Asensus Surgical has a market capitalization of $200.40 million and generates $3.17 million in revenue each year. The company earns $-59.31 million in net income (profit) each year or ($0.34) on an earnings per share basis.

How many employees does Asensus Surgical have?

Asensus Surgical employs 133 workers across the globe.

What is Asensus Surgical's official website?

The official website for Asensus Surgical is www.asensus.com.

Where are Asensus Surgical's headquarters?

Asensus Surgical is headquartered at 1 TW ALEXANDER DRIVE SUITE 160, DURHAM NC, 27703.

How can I contact Asensus Surgical?

Asensus Surgical's mailing address is 1 TW ALEXANDER DRIVE SUITE 160, DURHAM NC, 27703. The company can be reached via phone at (919) 765-8400, via email at [email protected], or via fax at 919-765-8459.


This page was last updated on 1/28/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.